CVS Health (NYSE:CVS) shares climbed around 5% in pre-market trading on Wednesday after the healthcare company reported second-quarter earnings that comfortably exceeded Wall Street expectations and increased its full-year profit forecast.
The company posted earnings of $2.58 per share for the quarter, well above the analyst consensus of $1.83. Revenue rose 7.3% from a year earlier to $106.1 billion, surpassing market expectations of $100.03 billion.
Health services business drives profit growth
Adjusted operating income increased 35.5% year over year to $5.15 billion, reflecting strong performance across the business.
The health services division, which includes CVS’s clinic operations, generated operating profit of $1.73 billion, up from $1.58 billion in the same quarter last year.
The company said the improvement was supported by changes to the operating model of its Oak Street primary care business.
MinuteClinic expands weight-loss treatment services
CVS also announced that its MinuteClinic locations will begin offering $29 consultations for adults seeking prescriptions for weight-loss medications.
The service will include access to treatments such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, further expanding the company’s healthcare offering as demand for obesity treatments continues to grow.
Company lifts full-year earnings forecast
Following the stronger quarterly performance, CVS increased its outlook for 2026.
The healthcare group now expects adjusted earnings per share of between $7.90 and $8.10 for the full year, compared with its previous guidance of $7.30 to $7.50.
The revised forecast also exceeded the Wall Street consensus estimate of $7.45 per share, reinforcing investor confidence and helping lift the stock in pre-market trading.
CVS Health stock price
